Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD - Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $7.15 billion for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 earnings per share. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Stock Down 2.0 %

NASDAQ GILD traded down $2.00 during trading on Friday, reaching $96.04. 7,182,199 shares of the company's stock were exchanged, compared to its average volume of 6,916,494. The company has a 50 day moving average price of $92.97 and a two-hundred day moving average price of $86.49. The stock has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $100.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 572,824 shares of company stock worth $53,611,715. Company insiders own 0.29% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Barclays boosted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Thursday, November 7th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Bank of America reissued a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.